Anti-MARH7/ MARCHF7/ AXO monoclonal antibody

Anti-MARH7/ MARCHF7/ AXO antibody for FACS & in-vivo assay

Target products collectionGo to MARCHF7/MARCHF7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2194-Ab-1/ GM-Tg-hg-MP2194-Ab-2Anti-Human MARCHF7 monoclonal antibodyHuman
GM-Tg-rg-MP2194-Ab-1/ GM-Tg-rg-MP2194-Ab-2Anti-Rat MARCHF7 monoclonal antibodyRat
GM-Tg-mg-MP2194-Ab-1/ GM-Tg-mg-MP2194-Ab-2Anti-Mouse MARCHF7 monoclonal antibodyMouse
GM-Tg-cynog-MP2194-Ab-1/ GM-Tg-cynog-MP2194-Ab-2Anti-Cynomolgus/ Rhesus macaque MARCHF7 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2194-Ab-1/ GM-Tg-felg-MP2194-Ab-2Anti-Feline MARCHF7 monoclonal antibodyFeline
GM-Tg-cang-MP2194-Ab-1/ GM-Tg-cang-MP2194-Ab-2Anti-Canine MARCHF7 monoclonal antibodyCanine
GM-Tg-bovg-MP2194-Ab-1/ GM-Tg-bovg-MP2194-Ab-2Anti-Bovine MARCHF7 monoclonal antibodyBovine
GM-Tg-equg-MP2194-Ab-1/ GM-Tg-equg-MP2194-Ab-2Anti-Equine MARCHF7 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2194-Ab-1/ GM-Tg-hg-MP2194-Ab-2; GM-Tg-rg-MP2194-Ab-1/ GM-Tg-rg-MP2194-Ab-2;
GM-Tg-mg-MP2194-Ab-1/ GM-Tg-mg-MP2194-Ab-2; GM-Tg-cynog-MP2194-Ab-1/ GM-Tg-cynog-MP2194-Ab-2;
GM-Tg-felg-MP2194-Ab-1/ GM-Tg-felg-MP2194-Ab-2; GM-Tg-cang-MP2194-Ab-1/ GM-Tg-cang-MP2194-Ab-2;
GM-Tg-bovg-MP2194-Ab-1/ GM-Tg-bovg-MP2194-Ab-2; GM-Tg-equg-MP2194-Ab-1/ GM-Tg-equg-MP2194-Ab-2
Products NameAnti-MARCHF7 monoclonal antibody
Formatmab
Target NameMARCHF7
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-MARCHF7 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species MARH7/ MARCHF7/ AXO VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2194
    Target NameMARCHF7
    Gene ID64844,57438,311059,703010,478763,101093628,507865,100051194
    Gene Symbol and SynonymsAXO,AXOT,Gtrgeo17,MARCH-VII,MARCH7,MARCHF7,RNF177
    Uniprot AccessionQ9H992,Q5XI50
    Uniprot Entry NameMARH7_HUMAN,MARH7_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000136536
    Target ClassificationN/A

    The target: MARCHF7, gene name: MARCHF7, also named as AXO, AXOT, MARCH-VII, RNF177. MARCH7 is a member of the MARCH family of membrane-bound E3 ubiquitin ligases (EC 6.3.2.19). MARCH proteins add ubiquitin (see MIM 191339) to target lysines in substrate proteins, thereby signaling their vesicular transport between membrane compartments (Bartee et al., 2004 [PubMed 14722266]).[supplied by OMIM, Mar 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.